<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01576887</url>
  </required_header>
  <id_info>
    <org_study_id>402-C-1201</org_study_id>
    <secondary_id>2012-001563-78</secondary_id>
    <nct_id>NCT01576887</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This study is a multi-center, double-blinded, randomized, study of bardoxolone methyl&#xD;
      treatment in patients with End-Stage Renal Disease (ERSD) and Type 2 Diabetes Mellitus (T2DM)&#xD;
      on peritoneal dialysis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    IDMC recommendation for safety concerns&#xD;
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>Approximately 17 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of Adverse Events</measure>
    <time_frame>Approximately 17 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Residual Renal Function</measure>
    <time_frame>Baseline to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180, 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum observed concentration</measure>
    <time_frame>Day 0, 30, 60, 90, 120, 150, 180, 210</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve</measure>
    <time_frame>2, 4, 8, 24 hours, 30, 60, 90, 120, 150 and 180 days</time_frame>
    <description>Only the first 8 patients randomized will have the PK drawn and hours 2, 4, 8, and 24. All patients will have the PK drawn at 30, 60, 90, 120, 150 and 180 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve</measure>
    <time_frame>2, 4, 8 and 24 hours</time_frame>
    <description>Only the first 8 patients randomized</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>End-Stage Renal Disease</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bardoxolone Methyl 20 mg</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Bardoxolone Methyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral, once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have ESRD and been on PD for longer than 3 months&#xD;
&#xD;
          2. Patients must have had a diagnosis of T2DM prior to starting dialysis&#xD;
&#xD;
          3. Patients must have RRF, as defined by the mean of urea and creatinine clearance on a&#xD;
             24 hour urine collection, ≥ 25 Liters/week/1.73 m2 documented in the four months prior&#xD;
             to the Screen A visit&#xD;
&#xD;
          4. Patients must have RRF, as defined by the mean of urea and creatinine clearances on a&#xD;
             24 hour urine collection, ≥ 25 Liters/week/1.73 m2 at both the Screen A and Screen B&#xD;
             visits&#xD;
&#xD;
          5. The RRF value obtained at the Screen B visit, must not be less than 50% of the RRF&#xD;
             value obtained at the Screen A visit&#xD;
&#xD;
          6. Patients must be at least 18 years of age&#xD;
&#xD;
          7. Patients must have a mean systolic blood pressure (SBP) on three readings at both&#xD;
             Screen A and Screen B visits ≤ 160 mmHg and ≥ 90 mmHg&#xD;
&#xD;
          8. Patients must have a mean diastolic blood pressure (DBP) on three readings at both&#xD;
             Screen A and Screen B visits &lt; 100 mmHg and ≥ 40 mmHg&#xD;
&#xD;
          9. Patients must be willing to practice methods of birth control (both males who have&#xD;
             partners of childbearing potential and females of childbearing potential) during&#xD;
             screening, while taking study drug and for at least 30 days after the last dose of&#xD;
             study drug is ingested&#xD;
&#xD;
         10. Patients must be willing and able to cooperate with all aspects of the protocol&#xD;
&#xD;
         11. Patients must be willing and able to give written informed consent to participate in&#xD;
             the study. They must provide consent for access to medical data according to&#xD;
             appropriate local data protection legislation and allow authorization to access&#xD;
             medical records that describe events captured in the endpoints&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of Autosomal Dominant Polycystic Kidney Disease&#xD;
&#xD;
          2. Currently Active Systemic Lupus Erythematosus&#xD;
&#xD;
          3. History of Hepatitis B Surface Antigen +&#xD;
&#xD;
          4. History of Hepatitis C Antibody + being treated with antiviral therapy&#xD;
&#xD;
          5. History of an organ transplant&#xD;
&#xD;
          6. A planned renal transplant from a living donor during the study&#xD;
&#xD;
          7. History of hospitalization for congestive heart failure or pulmonary edema within 12&#xD;
             weeks before study randomization&#xD;
&#xD;
          8. History of cirrhosis of the liver&#xD;
&#xD;
          9. History of amyloidosis or light chain nephropathy&#xD;
&#xD;
         10. History of hemoglobin A1c level &gt; 11.0% (97 mmol/mol) within 12 weeks before study&#xD;
             randomization&#xD;
&#xD;
         11. History of recently active cardiovascular disease defined as:&#xD;
&#xD;
               1. Unstable angina pectoris within 12 weeks before study randomization&#xD;
&#xD;
               2. Myocardial infarction, coronary artery bypass graft surgery, or percutaneous&#xD;
                  transluminal coronary angioplasty/stent within 12 weeks before study&#xD;
                  randomization&#xD;
&#xD;
               3. Cerebrovascular accident, including transient ischemic attack within 12 weeks&#xD;
                  before study randomization&#xD;
&#xD;
         12. History of a diagnostic or interventional procedure that required intravenous&#xD;
             administration of an iodinated contrast agent or gadolinium within 12 weeks before&#xD;
             study randomization&#xD;
&#xD;
         13. History of known severe obstructive valvular heart disease or severe obstructive&#xD;
             hypertrophic cardiomyopathy&#xD;
&#xD;
         14. History of known 2o or 3o atrioventricular block not successfully treated with a&#xD;
             pacemaker&#xD;
&#xD;
         15. History or resuscitated sudden cardiac death&#xD;
&#xD;
         16. History of an automatic implantable defibrillator&#xD;
&#xD;
         17. QTc greater than 0.50 seconds on an ECG obtained during either Screen A or Screen B&#xD;
             visits&#xD;
&#xD;
         18. A serum magnesium level less than 1.4 meq/L on either Screen A or Screen B visit&#xD;
             laboratory test results&#xD;
&#xD;
         19. History of systemic immunosuppression for more than 15 days, cumulatively, within the&#xD;
             12 weeks prior to study randomization or anticipated need for more than 15 days of&#xD;
             immunosuppression during the study&#xD;
&#xD;
         20. Total bilirubin, aspartate transaminase (AST), or alanine transaminase (ALT) level&#xD;
             greater than the upper limit of normal (ULN) or alkaline phosphatase level greater&#xD;
             than two times the ULN on either the Screen A and Screen B visit laboratory test&#xD;
             results&#xD;
&#xD;
         21. Known hypersensitivity to any component of the study drug&#xD;
&#xD;
         22. Current history of drug or alcohol abuse, as assessed by the investigator&#xD;
&#xD;
         23. History of clinically significant infection requiring intravenous administration of&#xD;
             antibiotics or hospitalization within 12 weeks before study randomization&#xD;
&#xD;
         24. In patients who have been on peritoneal dialysis for ≥ 6 months, two or more episodes&#xD;
             of peritonitis in the 6 months before study randomization. In patients who have been&#xD;
             on peritoneal dialysis for &lt;6 months, one episode of peritonitis before study&#xD;
             randomization&#xD;
&#xD;
         25. History of a diagnosis or treatment of a malignancy in the past 5 years, excluding&#xD;
             non-melanoma skin cancer and carcinoma in situ of the cervix&#xD;
&#xD;
         26. History of a clinical condition that, in the judgment of the investigator, could&#xD;
             potentially pose a health risk to the patient while involved in the study&#xD;
&#xD;
         27. Patient is unable to communicate or cooperate with the investigator due to language&#xD;
             problems, poor mental development, or impaired cerebral function&#xD;
&#xD;
         28. Participation in a clinical study involving any intervention within 30 days prior to&#xD;
             Screen A visit, concurrent participation in such a study, or participation in a prior&#xD;
             clinical study involving bardoxolone methyl in any form&#xD;
&#xD;
         29. Female patients who are pregnant, intend to become pregnant during this study, or are&#xD;
             nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2012</verification_date>
  <study_first_submitted>March 30, 2012</study_first_submitted>
  <study_first_submitted_qc>April 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2012</study_first_posted>
  <last_update_submitted>November 1, 2012</last_update_submitted>
  <last_update_submitted_qc>November 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

